Filing Flows › RenovoRx (RNXT) › Q2 2026
RenovoRx (RNXT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
RenovoRx (RNXT) reported revenue of $909K for the second quarter 2026 (Q2 2026), +115% from a year earlier and +61% from the quarter before. Operating margin was -368.4%, net loss $2.9M (320.2% of revenue).
RenovoRx, Q2 2026: revenue $909K (+115% year over year), operating margin -368.4%, net loss $2.9M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $909K | +61% | +115% |
| Operating profit | −$3.3M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$2.9M | — | — |
What changed
Revenue was $909K in Q2 2026, up 115% year over year and up 61% from the previous quarter.
Gross margin was 84.3%, up 20.3 points from Q2 2025. Operating costs exceeded revenue by $3.3M, an operating margin of -368.4%. Operating expenses grew 40% against revenue growth of 115%. The fastest-growing cost line was SG&A (+92%). The quarter ended with a net loss of $2.9M, narrower than the previous quarter's $3.5M loss.
Operating cash flow was −$2.9M. Non-cash charges added back $5K of depreciation and $570K of share-based compensation. Working capital and other items used $531K. Capital expenditures of $71K exceeded it, leaving free cash flow of −$2.9M.
Questions
What was RenovoRx's revenue in the second quarter 2026?
RenovoRx (RNXT) reported revenue of $909K for the second quarter 2026 (Q2 2026), +115% from a year earlier and +61% from the quarter before.
Was RenovoRx profitable in the second quarter 2026?
Operating loss was $3.3M (-368.4% of revenue) and net loss $2.9M.
Source: RenovoRx 10-Q on SEC EDGAR.